LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced the presentation of a poster highlighting data from a placebo-controlled study demonstrating that the controlled-release (CR) tablet formulation of zileuton (1200 mg BID), an investigational drug, was generally well tolerated and the adverse event profile was similar to placebo and similar to that seen with ZYFLO® (zileuton tablets), the immediate release (IR) formulation of zileuton currently marketed by the Company.
